Wolverine Asset Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Wolverine Asset Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-121,585	Closed	-$15.8K	–	1851
2024 Q4	$15.8K	Hold	121,585	–	–	﹤0.01%	1316
2024 Q3	$13.3K	Hold	121,585	–	–	﹤0.01%	1306
2024 Q2	$12.2K	Hold	121,585	–	–	﹤0.01%	1312
2024 Q1	$18.2K	Hold	121,585	–	–	﹤0.01%	1224
2023 Q4	$18.2K	Hold	121,585	–	–	﹤0.01%	1328
2023 Q3	$28K	Hold	121,585	–	–	﹤0.01%	1312
2023 Q2	$23.2K	Hold	121,585	–	–	﹤0.01%	1262
2023 Q1	$21.9K	Buy	+121,585	New	+$18.9K	﹤0.01%	1330

Wolverine Asset Management's BLACR Position: Q1 2025 in Review

Wolverine Asset Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 121,585 shares — an estimated $15.8K sold.

Wolverine Asset Management first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $28K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Wolverine Asset Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Wolverine Asset Management sold 121,585 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $15.8K.
Wolverine Asset Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Wolverine Asset Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $28K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.